Finanzen von BridgeBio Oncology Therapeutics Inc (BBOT)BBOTBridgeBio Oncology Therapeutics Inc

Evaluating the bottom line, BridgeBio Oncology Therapeutics Inc maintains a gross margin of N/A. This metric reflects the company's pricing power and manufacturing efficiency. Further down the income statement, the operating margin stands at N/A, while the net margin is N/A. These profitability ratios, combined with a Return on Equity (ROE) of -381.87%, provide a clear picture of how effectively BBOT converts its operational activities into shareholder value.

In the context of the broader market, BBOT competes directly with industry leaders such as RNAC and CRDL. With a market capitalization of $175.17M, it holds a significant position in the sector. When comparing efficiency, BBOT's gross margin of N/A stands against RNAC's 100.00% and CRDL's N/A. Such benchmarking helps identify whether BridgeBio Oncology Therapeutics Inc is trading at a premium or discount relative to its financial performance.

The financial performance is concerning, with a net income loss of $56.45 million reported in Q2 2026 and a forward P/E ratio of 0, indicating no expected earnings growth. The gross profit for 2026 is also negative, with no positive gross profit reported in recent quarters.